Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Immunotherapy for Multiple Myeloma
share announcement

Immunotherapy for Multiple Myeloma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 15 July 2024 | Viewed by 4183

Special Issue Editors

Dr. Meera Mohan

E-Mail Website
Guest Editor
Medical College of Wisconsin, Milwaukee, WI 53226, USA
Interests: multiple myeloma; immunotherapy; clinical trials; minimal residual disease
Dr. Carolina D. Schinke

E-Mail Website
Guest Editor
Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR 72205, USA
Interests: multiple myeloma; genomics; immunotherapy

Special Issue Information

Dear Colleagues,

Multiple myeloma (MM) is a genetically heterogenous disease that remains mostly incurable, with a small group of patients achieving long-term disease remission. In recent decades, we have witnessed unprecedented progress in the diagnostics and treatment of MM, particularily the advent of immunotherapeutic technologies such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. Currently, CAR-T therapy is approved for relapsed refractory MM, with several ongoing studies investigating its application in earlier lines of therapy including an upfront setting. Despite the impressive response in heavily pre-treated patients, we are now faced with several challenges including access to therapies, requirements for specialized setup for production and administration of CAR-T, management of toxicities, lack of predictive biomarkers and refractory disease. There is a pressing need for clinical and translational research addressing these concerns. This Special Issue reflects the recent developments in immunotherapy, working toward transforming myeloma into a curable disease.

Dr. Meera Mohan
Dr. Carolina D. Schinke
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma (MM)
  • bispecific antibodies
  • chimeric antigen receptor (CAR) T-cell therapy
  • immunotherapy
  • diagnostics and treatment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

23 pages, 8151 KiB  
Article
Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells
by Mouldy Sioud and Anniken Olberg
Cancers 2023, 15(7), 1934; https://doi.org/10.3390/cancers15071934 - 23 Mar 2023
Viewed by 1773
Abstract
Despite therapeutic advances in recent years, there are still unmet medical needs for patients with multiple myeloma (MM). Hence, new therapeutic strategies are needed. Using phage display for screening a large repertoire of single chain variable fragments (scFvs), we isolated several candidates that [...] Read more.
Despite therapeutic advances in recent years, there are still unmet medical needs for patients with multiple myeloma (MM). Hence, new therapeutic strategies are needed. Using phage display for screening a large repertoire of single chain variable fragments (scFvs), we isolated several candidates that recognize a heavily sulfated MM-specific glycoform of the surface antigen syndecan-1 (CD138). One of the engineered scFv-Fc antibodies, named MM1, activated NK cells and induced antibody-dependent cellular cytotoxicity against MM cells. Analysis of the binding specificity by competitive binding assays with various glycan ligands identified N-sulfation of glucosamine units as essential for binding. Additionally, site-directed mutagenesis revealed that the amino acids arginine and histidine in the complementarily determining regions (CDRs) 2 and 3 of the heavy chain are important for binding. Based on this observation, a heavy-chain antibody, known as a nanobody, and a peptide mimicking the CDR loop sequences were designed. Both variants exhibited high affinity and specificity to MM cells as compared to blood lymphocytes. Specific killing of MM cells was achieved by conjugating the CDR2/3 mimic peptide to a pro-apoptotic peptide (KLAKLAK)2. In a co-culture model, the fusion peptide killed MM cells, while leaving normal peripheral blood mononuclear cells unaffected. Collectively, the development of antibodies and peptides that detect tumor-specific glycoforms of therapeutic targets holds promise for improving targeted therapies and tumor imaging. Full article
(This article belongs to the Special Issue Immunotherapy for Multiple Myeloma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 351 KiB  
Review
Adoptive Immunotherapy and High-Risk Myeloma
by Catherine Duane, Michael O’Dwyer and Siobhan Glavey
Cancers 2023, 15(9), 2633; https://doi.org/10.3390/cancers15092633 - 6 May 2023
Cited by 1 | Viewed by 2084
Abstract
Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The recent development of immunotherapeutic [...] Read more.
Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The recent development of immunotherapeutic strategies, particularly T cell-based agents have changed the treatment landscape for patients with relapsed and refractory disease. Adoptive cellular therapies include chimeric antigen receptor (CAR) T cells, which have emerged as a highly promising therapy, particularly for patients with refractory disease. Other adoptive cellular approaches currently in trials include T cell receptor-based therapy (TCR), and the expansion of CAR technology to natural killer (NK) cells. In this review we explore the emerging therapeutic field of adoptive cellular therapy for MM, with a particular focus on the clinical impact of these therapies for patients with high-risk myeloma. Full article
(This article belongs to the Special Issue Immunotherapy for Multiple Myeloma)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop